Session Chairs
- Patrick D. Lyden
- Thomas Brott
Contact: James C. Grotta
Start time 2:30 p.m.
End time 5:00 p.m.
Participants
Jeffrey I. Frank
Anthony J. Furlan
James D. Gustafson
Randy Higashida
Chelsea Stella Kidwell
Thomas J. Kwiatkowski
Rose Marie Robertson
Marc Walton
Agenda
- Device trials (Higashida)
- Trial design - small focused vs. large
- NIH funding of translational device trials including Phase 1
- FDA re-prioritization to Phase 1 safety
- How to power
- How to get competing sponsors to work together
- How to select doses of each of the involved agents
- How to combine drugs and devices
- Stroke Center Designation (Kidwell)
- Medics need to take patients to designated centers
- Certification - can NIH certify?
- Should NIH recommend that some other group certify
- NIH should facilitate HCFA creating a certification
- Cooperative Clinical Trials Group (Johnson, Lyden)
- To select best trials to proceed
- Patterned after Canadian Consortium
- Select trials/sponsors/sites
- Acute stroke treatment infrastructure (Walton)
- Establish expertise and personnel
- Layer on that the research trials
- Comprehensive center to coordinate primary centers
- Clinical Trials Design (Spilker, Gustafsan)
- Need small focussed ground-breaking trials before large definitive
- Need acute (<3hour) therapy
- Need to combine with reperfusion
- Better Endpoints
- Role for Surrogate Markers
- Markers of Disease, ie the EKG for Stroke
- Diversity Issues (Johnson)
- Are minority patients less likely to be treated with t-PA
- What are the issues? Education? Infrastructure? Inner-City vs. suburban disparities in health care?
- Are strokes more severe based on race?
- Clot and Vessel Wall Interactions (Brott)
- Effect of clot on aged, non-compliant walls
- Endothelial injury mechanisms in large cerebral vessels
- What causes in-situ thrombosis
Last updated February 09, 2005